HK1246683B - 對於生產和用於注射裝置中是最佳的含有丙二醇的肽製劑 - Google Patents

對於生產和用於注射裝置中是最佳的含有丙二醇的肽製劑

Info

Publication number
HK1246683B
HK1246683B HK18106312.8A HK18106312A HK1246683B HK 1246683 B HK1246683 B HK 1246683B HK 18106312 A HK18106312 A HK 18106312A HK 1246683 B HK1246683 B HK 1246683B
Authority
HK
Hong Kong
Prior art keywords
optimal
production
propylene glycol
injection devices
containing peptide
Prior art date
Application number
HK18106312.8A
Other languages
English (en)
Inventor
Claude Bonde
Dorthe Kot Engelund
Tina Bjeldskov Pedersen
Original Assignee
Novo Nordisk As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34609967&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HK1246683(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novo Nordisk As filed Critical Novo Nordisk As
Publication of HK1246683B publication Critical patent/HK1246683B/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
HK18106312.8A 2003-11-20 2018-05-16 對於生產和用於注射裝置中是最佳的含有丙二醇的肽製劑 HK1246683B (zh)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DKPA200301719 2003-11-20

Publications (1)

Publication Number Publication Date
HK1246683B true HK1246683B (zh) 2019-11-15

Family

ID=34609967

Family Applications (1)

Application Number Title Priority Date Filing Date
HK18106312.8A HK1246683B (zh) 2003-11-20 2018-05-16 對於生產和用於注射裝置中是最佳的含有丙二醇的肽製劑

Country Status (20)

Country Link
US (5) US8114833B2 (zh)
EP (3) EP3300721B1 (zh)
JP (2) JP5558655B2 (zh)
KR (1) KR101243648B1 (zh)
CN (4) CN1882356B (zh)
AU (1) AU2004290862B2 (zh)
BR (1) BRPI0416743A (zh)
CA (1) CA2545034C (zh)
CY (1) CY1119723T1 (zh)
DK (2) DK1687019T3 (zh)
ES (2) ES2727854T3 (zh)
HK (1) HK1246683B (zh)
HU (2) HUE043210T2 (zh)
MX (1) MXPA06005581A (zh)
PL (2) PL3300721T3 (zh)
PT (2) PT3300721T (zh)
RU (1) RU2421238C2 (zh)
SI (2) SI3300721T1 (zh)
TR (1) TR201906789T4 (zh)
WO (1) WO2005049061A2 (zh)

Families Citing this family (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003002136A2 (en) * 2001-06-28 2003-01-09 Novo Nordisk A/S Stable formulation of modified glp-1
AU2004290862B2 (en) 2003-11-20 2010-06-03 Novo Nordisk A/S Propylene glycol-containing peptide formulations which are optimal for production and for use in injection devices
CA2663074A1 (en) 2006-09-22 2008-03-27 Novo Nordisk A/S Protease resistant insulin analogues
EP2152245B1 (en) 2007-04-30 2015-12-02 Novo Nordisk A/S Method for drying a protein composition, a dried protein composition and a pharmaceutical composition comprising the dried protein
EP2514406A1 (en) * 2007-06-01 2012-10-24 Novo Nordisk A/S Spontaneously dispersible preconcentrates including a peptide drug in a solid or semisolid carrier
CA2716159A1 (en) * 2007-06-01 2008-12-04 Novo Nordisk A/S Stable non-aqueous pharmaceutical compositions
US9260502B2 (en) 2008-03-14 2016-02-16 Novo Nordisk A/S Protease-stabilized insulin analogues
HUE032284T2 (en) 2008-03-18 2017-09-28 Novo Nordisk As Protease-stabilized, acylated insulin analogues
EP2111871A1 (de) * 2008-04-26 2009-10-28 Sandoz AG Stabilisierte Flüssigformulierung
US8031419B2 (en) 2009-07-28 2011-10-04 Hong Kong Applied Science and Technology Research Institute, Co., Ltd. Compact imaging device
US20110097386A1 (en) * 2009-10-22 2011-04-28 Biodel, Inc. Stabilized glucagon solutions
US9610329B2 (en) * 2009-10-22 2017-04-04 Albireo Pharma, Inc. Stabilized glucagon solutions
US8263578B2 (en) 2010-03-18 2012-09-11 Innopharma, Inc. Stable bortezomib formulations
JP5661912B2 (ja) * 2010-03-18 2015-01-28 イノファーマ，インコーポレイテッド 安定なボルテゾミブ製剤
EP3326620B1 (en) 2010-12-16 2020-03-04 Novo Nordisk A/S Solid compositions comprising a glp-1 agonist and a salt of n-(8-(2- hydroxybenzoyl)amino)caprylic acid
CA2832811A1 (en) 2011-04-12 2012-10-18 Novo Nordisk A/S Double-acylated glp-1 derivatives
AU2012293463B2 (en) * 2011-08-10 2016-08-04 Adocia Injectable solution of at least one type of basal insulin
EP4324475A1 (en) 2012-03-22 2024-02-21 Novo Nordisk A/S Compositions of glp-1 peptides and preparation thereof
KR20150002777A (ko) 2012-04-11 2015-01-07 노보 노르디스크 에이/에스 인슐린 제제
US9993430B2 (en) 2012-06-20 2018-06-12 Novo Nordisk A/S Tablet formulation comprising semaglutide and a delivery agent
CA2877056A1 (en) 2012-07-01 2014-01-09 Novo Nordisk A/S Use of long-acting glp-1 peptides
UA116217C2 (uk) 2012-10-09 2018-02-26 Санофі Пептидна сполука як подвійний агоніст рецепторів glp1-1 та глюкагону
UA116553C2 (uk) 2012-12-21 2018-04-10 Санофі Пептидна сполука - агоніст рецептора glp-1 i glp
CN103893744B (zh) * 2012-12-24 2017-12-19 杭州九源基因工程有限公司 一种治疗糖尿病的药物制剂及其制备方法
TWI641381B (zh) * 2013-02-04 2018-11-21 法商賽諾菲公司 胰島素類似物及／或胰島素衍生物之穩定化醫藥調配物
US9738697B2 (en) 2013-06-23 2017-08-22 Wisconsin Alumni Research Foundation Alpha/beta-polypeptide analogs of glucagon-like peptide-1
CN104415326A (zh) * 2013-08-28 2015-03-18 深圳翰宇药业股份有限公司 一种含有利拉鲁肽的药物制剂组合物及其制备方法
PL3055325T3 (pl) 2013-10-07 2018-06-29 Novo Nordisk A/S Nowa pochodna analogu insuliny
TW201609799A (zh) 2013-12-13 2016-03-16 賽諾菲公司 雙重ｇｌｐ－１／ｇｉｐ受體促效劑
WO2015086730A1 (en) 2013-12-13 2015-06-18 Sanofi Non-acylated exendin-4 peptide analogues
TW201609797A (zh) 2013-12-13 2016-03-16 賽諾菲公司 雙重ｇｌｐ－１／升糖素受體促效劑
TW201609795A (zh) 2013-12-13 2016-03-16 賽諾菲公司 作為雙重ｇｌｐ－１／ｇｉｐ受體促效劑的艾塞那肽－４（ｅｘｅｎｄｉｎ－４）胜肽類似物
US9839692B2 (en) 2014-01-09 2017-12-12 Sanofi Stabilized pharmaceutical formulations of insulin analogues and/or insulin derivatives
TW201625669A (zh) 2014-04-07 2016-07-16 賽諾菲公司 衍生自艾塞那肽－４（Ｅｘｅｎｄｉｎ－４）之肽類雙重ＧＬＰ－１／升糖素受體促效劑
TW201625668A (zh) 2014-04-07 2016-07-16 賽諾菲公司 作為胜肽性雙重ｇｌｐ－１／昇糖素受體激動劑之艾塞那肽－４衍生物
TW201625670A (zh) 2014-04-07 2016-07-16 賽諾菲公司 衍生自ｅｘｅｎｄｉｎ－４之雙重ｇｌｐ－１／升糖素受體促效劑
US9932381B2 (en) 2014-06-18 2018-04-03 Sanofi Exendin-4 derivatives as selective glucagon receptor agonists
WO2016038521A1 (en) * 2014-09-08 2016-03-17 Sun Pharmaceutical Industries Limited Pharmaceutical compositions of liraglutide
WO2016059593A1 (en) * 2014-10-16 2016-04-21 Piramal Enterprises Limited Stable injectable composition of protein drugs and process for its preparation
EP3295952B1 (en) * 2015-05-13 2021-02-17 Hangzhou Jiuyuan Gene Engineering Co., Ltd Pharmaceutical formulation comprising glp-1 analogue and preparation method thereof
EP3297653B1 (en) 2015-05-22 2021-09-15 The Board of Trustees of the Leland Stanford Junior University Treatment of post-bariatric hypoglycemia with glp-1 antagonists
AR105319A1 (es) 2015-06-05 2017-09-27 Sanofi Sa Profármacos que comprenden un conjugado agonista dual de glp-1 / glucagón conector ácido hialurónico
AR105284A1 (es) 2015-07-10 2017-09-20 Sanofi Sa Derivados de exendina-4 como agonistas peptídicos duales específicos de los receptores de glp-1 / glucagón
JP2019506440A (ja) * 2016-03-01 2019-03-07 深▲せん▼翰宇薬業股▲ふん▼有限公司Ｈｙｂｉｏ Ｐｈａｒｍａｃｅｕｔｉｃａｌ Ｃｏ．， Ｌｔｄ． 医薬組成物及びその製造方法
WO2017149105A1 (en) * 2016-03-04 2017-09-08 Novo Nordisk A/S Liraglutide in renal conditions
US9968659B2 (en) * 2016-03-04 2018-05-15 Novo Nordisk A/S Liraglutide in cardiovascular conditions
US10653753B2 (en) 2016-03-04 2020-05-19 Eiger Biopharmaceuticals, Inc. Treatment of hyperinsulinemic hypoglycemia with exendin-4 derivatives
WO2017220463A1 (en) * 2016-06-20 2017-12-28 Isa Pharmaceuticals B.V. Formulation of a peptide vaccine
US10350293B2 (en) 2016-08-23 2019-07-16 Pharmacotherapia d.o.o. Compositions and methods for treating symptoms associated with multiple sclerosis
EP3515408A1 (en) 2016-09-23 2019-07-31 Delpor, Inc. Stable compositions for incretin mimetic compounds
JP2019535734A (ja) 2016-11-21 2019-12-12 アイガー・バイオファーマシューティカルズ・インコーポレイテッドＥｉｇｅｒ Ｂｉｏｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． エキセンディン（９−３９）の緩衝製剤
DK3554534T3 (da) 2016-12-16 2021-08-23 Novo Nordisk As Farmaceutisk sammensætning omfattende insulin
GB201621987D0 (en) * 2016-12-22 2017-02-08 Archer Virgil L See Archer Sheri A Arecor Ltd Novel composition
CN111050750A (zh) 2017-08-24 2020-04-21 诺沃挪第克公司 Glp-1组合物及其用途
PL3746111T3 (pl) 2018-02-02 2024-01-15 Novo Nordisk A/S Stałe kompozycje zawierające agonistę glp-1 i sól kwasu n-(8-(2- hydroksybenzoilo)amino kaprylowego i substancję poślizgową
WO2019200594A1 (zh) 2018-04-19 2019-10-24 杭州先为达生物科技有限公司 酰化的glp-1衍生物
TWI705820B (zh) * 2018-06-22 2020-10-01 美商美國禮來大藥廠 Gip/glp1促效劑組合物
EP3628682A1 (en) 2018-09-28 2020-04-01 Zealand Pharma A/S Formulations of glucagon-like-peptide-2 (glp-2) analogues
US11058745B1 (en) 2018-10-04 2021-07-13 Good Health, Llc Stable liquid pharmaceutical compositions of daptomycin
BR112021006643A8 (pt) * 2018-10-09 2022-12-06 B Schaal Justin Composições e métodos para aumentar capacidade de distribuição sistêmica, tolerância e eficácia de peptídeos macrocíclicos catiônicos
BR112021006598A2 (pt) 2018-10-26 2021-07-06 Novo Nordisk As composição farmacêutica líquida, e, kit
EP3897570A1 (en) 2018-12-19 2021-10-27 KRKA, d.d., Novo mesto Pharmaceutical composition comprising glp-1 analogue
US11471512B2 (en) 2019-03-01 2022-10-18 Merck Sharp & Dohme Llc Pharmaceutical compositions of a peptide
WO2020208541A1 (en) * 2019-04-08 2020-10-15 Enzene Biosciences Limited Composition comprising glp-1 analogue
WO2021123228A1 (en) 2019-12-18 2021-06-24 Krka, D.D., Novo Mesto Pharmaceutical composition comprising glp-1 analogue
CN115135305A (zh) 2020-02-18 2022-09-30 诺和诺德股份有限公司 药物制剂
US20230110689A1 (en) 2020-03-30 2023-04-13 Zealand Pharma A/S Agonist combination
US11478533B2 (en) 2020-04-27 2022-10-25 Novo Nordisk A/S Semaglutide for use in medicine
AU2022263996A1 (en) 2021-04-27 2023-11-02 Aardvark Therapeutics, Inc. Combination of bitter receptor agonist and gut-signaling compound

Family Cites Families (118)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU542560B2 (en) 1980-03-21 1985-02-28 Wellcome Foundation Limited, The Stabilised ophthalmic solution
US4483849A (en) 1983-01-07 1984-11-20 Carter William A Stabilization and purification of interferon with propylene glycol, resulting in a non-toxic product
US4468346A (en) * 1983-10-27 1984-08-28 The United States Of America As Represented By The Secretary Of Agriculture Monoclonal antibodies to porcine immunoglobulins
PH25772A (en) 1985-08-30 1991-10-18 Novo Industri As Insulin analogues, process for their preparation
DE3750402T3 (de) 1986-05-05 1997-04-10 Gen Hospital Corp Insulinotropes hormon.
NZ224615A (en) * 1987-05-14 1990-04-26 Commw Scient Ind Res Org Process for the production of whey protein fractions
EP0422124A4 (en) 1988-06-27 1991-10-16 Genex Corporation Thermal release of recombinant protein into culture media
DE3837825A1 (de) 1988-11-08 1990-05-10 Hoechst Ag Neue insulinderivate, ihre verwendung und eine sie enthaltende pharmazeutische zubereitung
HUT56857A (en) 1988-12-23 1991-10-28 Novo Nordisk As Human insulin analogues
NZ232375A (en) 1989-02-09 1992-04-28 Lilly Co Eli Insulin analogues modified at b29
DE68929217T2 (de) 1989-03-20 2000-11-30 Gen Hospital Corp Insulinotropes hormon
JP2822447B2 (ja) * 1989-05-19 1998-11-11 住友電気工業株式会社 酸化物超電導線材の製造方法および装置
US5216011A (en) 1989-09-01 1993-06-01 Bristol-Myers Squibb Co. Stable solutions of mitomycin c
EP0431679B1 (en) 1989-12-05 1994-10-19 Merck & Co. Inc. Method of stabilizing recombinant hepatitis B virus surface proteins from yeast
DE69129226T2 (de) 1990-01-24 1998-07-30 Douglas I Buckley Glp-1-analoga verwendbar in der diabetesbehandlung
DE4002066A1 (de) 1990-01-25 1991-08-01 Basf Ag Verfahren zur abtrennung von riboflavin aus fermentationssuspensionen
DE69103120T2 (de) * 1990-10-26 1995-03-30 Furukawa Electric Co Ltd Polyphenylensulfid-Zusammensetzung für Pulverbeschichtung.
US5272135A (en) 1991-03-01 1993-12-21 Chiron Ophthalmics, Inc. Method for the stabilization of methionine-containing polypeptides
SE9101381D0 (sv) * 1991-05-07 1991-05-07 Tomas Moks Peptide hormone solution
US5206219A (en) * 1991-11-25 1993-04-27 Applied Analytical Industries, Inc. Oral compositions of proteinaceous medicaments
DK36492D0 (da) 1992-03-19 1992-03-19 Novo Nordisk As Praeparat
DK39892D0 (da) 1992-03-25 1992-03-25 Bernard Thorens Peptid
DK0642332T3 (da) * 1992-05-13 1997-06-16 Sandoz Ltd Ophthalmiske præparater indeholdende cyclosporin
US6284727B1 (en) * 1993-04-07 2001-09-04 Scios, Inc. Prolonged delivery of peptides
US5424286A (en) 1993-05-24 1995-06-13 Eng; John Exendin-3 and exendin-4 polypeptides, and pharmaceutical compositions comprising same
ATE176482T1 (de) 1993-06-21 1999-02-15 Novo Nordisk As Asp-b28-insulinkristalle
WO1995005848A1 (en) * 1993-08-24 1995-03-02 Novo Nordisk A/S Protracted glp-1
US6011007A (en) 1993-09-17 2000-01-04 Novo Nordisk A/S Acylated insulin
EP1132404A3 (en) 1993-09-17 2002-03-27 Novo Nordisk A/S Acylated insulin
GB9320782D0 (en) 1993-10-08 1993-12-01 Univ Leeds Innovations Ltd Stabilising of proteins on solution
PT729362E (pt) * 1993-11-19 2000-06-30 Searle & Co Composicao transdermica de n-¬n-¬5-¬4-(aminoiminometil)fenil|-1oxopentil|-l-alfa-aspartil|-l-fenillalanina ou esteres e seus sais farmaceuticamente aceitaveis
US5705483A (en) * 1993-12-09 1998-01-06 Eli Lilly And Company Glucagon-like insulinotropic peptides, compositions and methods
WO1995022560A1 (en) * 1994-02-22 1995-08-24 The Syntex-Synergen Neuroscience Joint Venture Pharmaceutical formulations of cntf
US5652216A (en) * 1994-05-26 1997-07-29 Novo Nordisk A/S Pharmaceutical preparation
US5504188A (en) 1994-06-16 1996-04-02 Eli Lilly And Company Preparation of stable zinc insulin analog crystals
US5574008A (en) 1994-08-30 1996-11-12 Eli Lilly And Company Biologically active fragments of glucagon-like insulinotropic peptide
DE69532492T2 (de) 1994-08-31 2004-12-02 Mitsubishi Pharma Corp. Verfahren zur Reinigung von rekombinantem menschlichem Serumalbumin
US5512549A (en) 1994-10-18 1996-04-30 Eli Lilly And Company Glucagon-like insulinotropic peptide analogs, compositions, and methods of use
EP0796106B1 (en) 1994-12-23 2003-03-19 Novo Nordisk A/S Protracted glp-1 compositions
EP0820299B1 (en) 1995-02-06 2002-04-24 Genetics Institute, Inc. Formulations for il-12
US6184201B1 (en) * 1995-04-14 2001-02-06 Nps Allelix Corp. Intestinotrophic glucagon-like peptide-2 analogs
US5834428A (en) * 1995-04-14 1998-11-10 1149336 Ontario Inc. Glucagon-like peptide-2 and its therapeutic use
DK0828753T3 (da) 1995-06-02 2003-06-30 Novozymes As A1/Fe-behandling af en proteinopløsning efterfulgt af membranopkoncentrering
US5631347A (en) 1995-06-07 1997-05-20 Eli Lilly And Company Reducing gelation of a fatty acid-acylated protein
AU723694B2 (en) 1996-06-05 2000-08-31 Roche Diagnostics Gmbh Exendin analogues, processes for their preparation and medicaments containing them
RO119862B1 (ro) * 1996-07-03 2005-05-30 Alza Corporation Formulare stabilă neapoasă şi procedeu pentru prepararea acesteia
US5981489A (en) 1996-07-18 1999-11-09 Alza Corporation Non-aqueous protic peptide formulations
DE69739172D1 (de) 1996-08-08 2009-01-29 Amylin Pharmaceuticals Inc Regulation gastrointestinaler beweglichkeit
JPH10101696A (ja) 1996-08-08 1998-04-21 Shinotesuto:Kk 形質転換体にて発現される蛋白質に含まれる夾雑物質の除去方法及び精製蛋白質
DK0944648T3 (da) 1996-08-30 2007-07-02 Novo Nordisk As GLP-1 derivater
US6268343B1 (en) * 1996-08-30 2001-07-31 Novo Nordisk A/S Derivatives of GLP-1 analogs
PT1629849E (pt) 1997-01-07 2013-07-09 Amylin Pharmaceuticals Llc Composições farmacêuticas que compreendem exendinas e seus agonistas
EP0998942A4 (en) * 1997-01-20 2006-08-16 Japan Energy Corp METHOD FOR STABILIZING PEPTIDES AND FREEZERED MEDICINAL COMPOSITIONS THEREOF
WO1998043658A1 (en) 1997-03-31 1998-10-08 Eli Lilly And Company Glucagon-like peptide-1 analogs
CA2236519C (en) * 1997-05-02 2011-09-13 1149336 Ontario Inc. Methods of enhancing functioning of the large intestine
CO4750643A1 (es) 1997-06-13 1999-03-31 Lilly Co Eli Formulacion estable de la insulina que contiene l-arginina y protamina
DE69738333T2 (de) * 1997-10-01 2008-11-27 Novadel Pharma Inc. Nichtpolares Spray zur bukkalen Verabreichung
PT1025126E (pt) 1997-10-24 2003-09-30 Genentech Inc Purificacao de moleculas
CA2312190A1 (en) 1997-12-05 1999-06-17 Eli Lilly And Company Glp-1 formulations
MY120063A (en) 1997-12-09 2005-08-30 Lilly Co Eli Stabilized teriparatide solutions
US6380357B2 (en) 1997-12-16 2002-04-30 Eli Lilly And Company Glucagon-like peptide-1 crystals
DE69942306D1 (de) 1998-02-27 2010-06-10 Novo Nordisk As Abkömmlinge von glp-1 analogen
AU2610599A (en) 1998-02-27 1999-09-15 Novo Nordisk A/S N-terminally truncated glp-1 derivatives
AU2610899A (en) 1998-02-27 1999-09-15 Novo Nordisk A/S N-terminally modified glp-1 derivatives
ATE265224T1 (de) 1998-02-27 2004-05-15 Novo Nordisk As Glp-1 derivate mit einem helix-gehalt über 25 , die partiell strukturierte mizellenartige aggregate bilden
EP1056775B1 (en) 1998-02-27 2010-04-28 Novo Nordisk A/S Glp-1 derivatives of glp-1 and exendin with protracted profile of action
DE69918070T2 (de) * 1998-03-13 2005-08-25 Novo Nordisk A/S Stabilisierte, wässrige Glukagonlösungen, enthaltend Detergenzien
WO2000015224A1 (en) 1998-09-17 2000-03-23 Eli Lilly And Company Protein formulations
ATE307603T1 (de) * 1998-12-22 2005-11-15 Lilly Co Eli Lagerstabile flüssige zusammensetzungen von glucagon-ähnlichem peptid-1
EP1140145B2 (en) 1999-01-14 2019-05-15 Amylin Pharmaceuticals, LLC Novel exendin agonist formulations and methods of administration thereof
US6444788B1 (en) * 1999-03-15 2002-09-03 Novo Nordisk A/S Ion exchange chromatography of GLP-1, analogs and derivatives thereof
PL351326A1 (en) 1999-03-17 2003-04-07 Novo Nordisk As Method for acylating peptides and novel acylating agents
CA2369839A1 (en) 1999-06-25 2001-01-04 Minimed, Inc. Compositions of insulin and insulin-related peptide for treating diabetes
EP1076066A1 (en) 1999-07-12 2001-02-14 Zealand Pharmaceuticals A/S Peptides for lowering blood glucose levels
DE60024118T2 (de) 1999-09-20 2006-07-27 Eli Lilly And Co., Indianapolis Verwendung einer parathyroidhormone zur reduktion des krebsrisikos
US7022674B2 (en) * 1999-12-16 2006-04-04 Eli Lilly And Company Polypeptide compositions with improved stability
DE60018105T2 (de) 1999-12-16 2005-12-29 Eli Lilly And Co., Indianapolis Polypeptidzusammensetzungen mit verbesserter stabilität
GB9930882D0 (en) 1999-12-30 2000-02-23 Nps Allelix Corp GLP-2 formulations
WO2001051071A2 (en) 2000-01-11 2001-07-19 Novo Nordisk A/S Transepithelial delivery of glp-1 derivatives
US20010012829A1 (en) * 2000-01-11 2001-08-09 Keith Anderson Transepithelial delivery GLP-1 derivatives
US6734162B2 (en) 2000-01-24 2004-05-11 Minimed Inc. Mixed buffer system for stabilizing polypeptide formulations
EP1396499A3 (en) 2000-01-27 2004-12-29 Eli Lilly And Company Process for solubilizing glucagon-like peptide 1 (GLP-1) compounds
ES2218381T3 (es) 2000-01-27 2004-11-16 Eli Lilly And Company Procedimiento para solubilizar compuestos del peptido 1 de tipo glucagon.
US6569901B2 (en) * 2000-01-28 2003-05-27 Novo Nordisk A/S Alkynyl-substituted propionic acid derivatives, their preparation and use
US6844321B2 (en) * 2000-01-31 2005-01-18 Novo Nordisk A/S Crystallization of a GLP-1 analogue
AU2001248277A1 (en) 2000-04-06 2001-10-23 Novo-Nordisk A/S Shock heat treatment of polypeptides
AU6479101A (en) 2000-06-16 2002-01-02 Lilly Co Eli Glucagon-like peptide-1 analogs
JP4798833B2 (ja) 2000-10-24 2011-10-19 一般財団法人化学及血清療法研究所 加熱処理工程を含むヒト血清アルブミンの製造方法
US7271149B2 (en) 2000-12-07 2007-09-18 Eli Lilly And Company GLP-1 fusion proteins
MXPA03005135A (es) 2000-12-13 2003-12-04 Lilly Co Eli Regimen de tratamiento cronico usando peptidos insulinotropicos similares al glucagon.
WO2002048192A2 (en) 2000-12-13 2002-06-20 Eli Lilly And Company Amidated glucagon-like peptide-1
US20020151467A1 (en) * 2000-12-21 2002-10-17 Leung Frank K. Methods and compositions for oral insulin delivery
GB2371227A (en) * 2001-01-10 2002-07-24 Grandis Biotech Gmbh Crystallisation - resistant aqueous growth hormone formulations
EP1360202B1 (en) * 2001-02-16 2008-05-21 ConjuChem Biotechnologies Inc. Long lasting glucagon-like peptide 2 (glp-2) for the treatment of gastrointestinal diseases and disorders
US6573237B2 (en) * 2001-03-16 2003-06-03 Eli Lilly And Company Protein formulations
WO2002074978A2 (en) * 2001-03-19 2002-09-26 President And Fellows Of Harvard College Nucleic acid shuffling
US20040156835A1 (en) * 2001-05-30 2004-08-12 Taiji Imoto Protein preparation
WO2003002136A2 (en) * 2001-06-28 2003-01-09 Novo Nordisk A/S Stable formulation of modified glp-1
US6872705B2 (en) 2001-07-13 2005-03-29 Allergan, Inc. Use of antimicrobial peptides as preservatives in ophthalmic preparations, including solutions, emulsions, and suspensions
CN1335182A (zh) * 2001-08-08 2002-02-13 华中科技大学 胰岛素口腔喷剂及其制备工艺
EP1432430A4 (en) * 2001-08-28 2006-05-10 Lilly Co Eli PREMIXTURES OF GLP-1 AND BASALINSULIN
NZ531788A (en) 2001-10-18 2008-01-31 Bristol Myers Squibb Co Human glucagon-like-peptide-1 mimics and their use in the treatment of diabetes and related conditions
EP1448222A4 (en) 2001-10-19 2006-05-17 Lilly Co Eli BIPHASIC MIXTURES OF GLP-1 AND INSULIN
EP1344533B1 (en) 2002-03-15 2006-08-23 Natimmune A/S Pharmaceutical compositions comprising mannose binding lectin
JP2005535569A (ja) * 2002-04-04 2005-11-24 ノボ・ノルデイスク・エー／エス Ｇｌｐ−１アゴニスト及び心臓血管合併症
AU2003266216A1 (en) 2002-09-25 2004-04-19 Novo Nordisk A/S Purification process comprising microfiltration at elevated temperatures
US6969702B2 (en) 2002-11-20 2005-11-29 Neuronova Ab Compounds and methods for increasing neurogenesis
WO2004089985A1 (en) * 2003-04-11 2004-10-21 Novo Nordisk A/S Stable pharmaceutical compositions
US8008255B2 (en) 2003-05-30 2011-08-30 Amylin Pharmaceuticals, Inc. Methods and compositions for enhanced transmucosal delivery of peptides and proteins
PL1633390T3 (pl) 2003-06-03 2012-06-29 Novo Nordisk As Stabilizowane kompozycje farmaceutyczne peptydu glp-1
US20060287221A1 (en) 2003-11-13 2006-12-21 Novo Nordisk A/S Soluble pharmaceutical compositions for parenteral administration comprising a GLP-1 peptide and an insulin peptide of short time action for treatment of diabetes and bulimia
EP1684793B1 (en) 2003-11-13 2011-09-21 Novo Nordisk A/S Pharmaceutical composition comprising an insulinotropic glp-1(7-37) analogue, asp(b28)-insulin, and a surfactant
AU2004290862B2 (en) * 2003-11-20 2010-06-03 Novo Nordisk A/S Propylene glycol-containing peptide formulations which are optimal for production and for use in injection devices
US20060286129A1 (en) * 2003-12-19 2006-12-21 Emisphere Technologies, Inc. Oral GLP-1 formulations
JP5248113B2 (ja) * 2004-11-12 2013-07-31 ノヴォ ノルディスク アー／エス ペプチドの安定な処方
GB0704846D0 (en) * 2007-03-13 2007-04-18 Futura Medical Dev Ltd Topical pharmaceutical formulation
EP2670390A2 (en) * 2011-02-04 2013-12-11 Biocopea Limited Compostions and methods for treating chronic inflammation and inflammatory diseases
CN102579350B (zh) * 2012-03-02 2013-04-24 海南灵康制药有限公司 右旋布洛芬脂质体固体制剂

Also Published As

Publication number Publication date
AU2004290862A1 (en) 2005-06-02
HUE038395T2 (hu) 2018-10-29
US20230364241A1 (en) 2023-11-16
KR101243648B1 (ko) 2013-03-14
ES2727854T3 (es) 2019-10-21
EP3300721A1 (en) 2018-04-04
CN102784386A (zh) 2012-11-21
MXPA06005581A (es) 2006-08-11
PT3300721T (pt) 2019-06-06
JP2012188424A (ja) 2012-10-04
SI3300721T1 (sl) 2019-07-31
US20190231876A1 (en) 2019-08-01
DK1687019T3 (en) 2018-02-12
CA2545034A1 (en) 2005-06-02
CN1882356A (zh) 2006-12-20
JP5558655B2 (ja) 2014-07-23
WO2005049061A8 (en) 2005-12-01
CN1882356B (zh) 2015-02-25
CN104826116A (zh) 2015-08-12
SI1687019T1 (en) 2018-04-30
EP3300721B1 (en) 2019-03-06
HUE043210T2 (hu) 2019-08-28
US8114833B2 (en) 2012-02-14
US20070010424A1 (en) 2007-01-11
EP1687019B1 (en) 2017-11-22
RU2006116414A (ru) 2007-12-27
BRPI0416743A (pt) 2007-01-16
JP2007513084A (ja) 2007-05-24
CN113304250A (zh) 2021-08-27
WO2005049061A2 (en) 2005-06-02
EP2394656B1 (en) 2023-12-13
CY1119723T1 (el) 2018-06-27
KR20060100428A (ko) 2006-09-20
EP1687019A2 (en) 2006-08-09
EP2394656A2 (en) 2011-12-14
CA2545034C (en) 2013-03-05
EP2394656A3 (en) 2012-01-18
AU2004290862B2 (en) 2010-06-03
US20120225810A1 (en) 2012-09-06
US20200316204A1 (en) 2020-10-08
JP5670373B2 (ja) 2015-02-18
WO2005049061A3 (en) 2005-10-20
TR201906789T4 (tr) 2019-05-21
DK3300721T3 (da) 2019-05-27
ES2660320T3 (es) 2018-03-21
PL3300721T3 (pl) 2019-08-30
PT1687019T (pt) 2018-02-26
PL1687019T3 (pl) 2018-05-30
RU2421238C2 (ru) 2011-06-20

Similar Documents

Publication Publication Date Title
HK1246683B (zh) 對於生產和用於注射裝置中是最佳的含有丙二醇的肽製劑
IL176006A0 (en) Immunogenic peptide carrier conjugates and methods for producing the same
IL162642A0 (en) Formulations
IL164519A0 (en) Pharmaceutical formulations
IL172824A0 (en) Pharmaceutical formulations
GB0302671D0 (en) Pharmaceutical formulations
GB0206461D0 (en) Improvements in vaccination
AU2003239248A8 (en) Anti-cd30 stalk and anti-cd30 antibodies suitable for use in immunotoxins
GB0323701D0 (en) Formulations
GB2392093B (en) Pharmaceutical formulations
GB0302672D0 (en) Pharmaceutical formulations
GB0324265D0 (en) Peptide
AU2003228863A8 (en) Immunogenic peptides
GB0316341D0 (en) Pharmaceutical formulations
EP1549291A4 (en) INJECTION FORMULATION
GB0307765D0 (en) Tissue-adhesive formulations
GB0317376D0 (en) Immunogenic protein and uses thereof
GB0311936D0 (en) Improvements in devices
EP1699809A4 (en) PEPTIDE FROM AMNIOTIC LIQUID AND USES THEREOF
GB0213005D0 (en) Injection nozzle
TW563410U (en) Combining plastic blocks used in gardens
GB0316335D0 (en) Pharmaceutical formulations
EP1551330A4 (en) IMPROVEMENTS IN THE TECHNOLOGY OF THE CONTRIBUTION
GB0315664D0 (en) Nozzle arrangements
TW580950U (en) Improved nozzle head structure for use in horticulture